Investigators Present Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in…
Patients treated in dose-escalation portion of Phase 1/2 study evaluating seclidemstat in combination with azacitidine 50% overall response rate among eight myelodysplastic syndrome (MDS)…